An Efficacy and Safety Study of Infliximab Dose Escalation in Pediatric Participants With Inflammatory Bowel Disease
- First Posted Date
- 2015-10-02
- Last Posted Date
- 2020-08-06
- Lead Sponsor
- Janssen Scientific Affairs, LLC
- Target Recruit Count
- 53
- Registration Number
- NCT02566889
A Study to Assess the Independent Effects of 4-Factor Prothrombin Complex Concentrate and Tranexamic Acid on Bleeding/Pharmacodynamics in Healthy Participants
Phase 1
Completed
- Conditions
- Healthy
- Interventions
- First Posted Date
- 2015-09-28
- Last Posted Date
- 2017-06-14
- Lead Sponsor
- Janssen Scientific Affairs, LLC
- Target Recruit Count
- 158
- Registration Number
- NCT02561923
A Study to Compare Disease Progression and Modification Following Treatment With Paliperidone Palmitate Long-Acting Injection or Oral Antipsychotics in Participant's With Recent-onset Schizophrenia or Schizophreniform
Phase 3
Completed
- Conditions
- SchizophreniaPsychotic Disorders
- Interventions
- First Posted Date
- 2015-05-01
- Last Posted Date
- 2021-12-03
- Lead Sponsor
- Janssen Scientific Affairs, LLC
- Target Recruit Count
- 337
- Registration Number
- NCT02431702
Study to Evaluate the Effects of Tramadol Hydrochloride on Cardiac Repolarization in Healthy Participants
Phase 1
Completed
- Conditions
- Healthy
- Interventions
- First Posted Date
- 2014-12-04
- Last Posted Date
- 2018-08-29
- Lead Sponsor
- Janssen Scientific Affairs, LLC
- Target Recruit Count
- 68
- Registration Number
- NCT02307864
An Efficacy and Safety Study of Simeprevir and Sofosbuvir With and Without Ribavirin in Participants With Recurrent Genotype 1 Hepatitis C Post-Orthotopic Liver Transplant
- First Posted Date
- 2014-06-17
- Last Posted Date
- 2016-11-11
- Lead Sponsor
- Janssen Scientific Affairs, LLC
- Target Recruit Count
- 46
- Registration Number
- NCT02165189
A Study to Examine Patient Characteristics, Health Care Management and Health Outcomes of Hepatitis C Virus (HCV) Patients Treated With Simeprevir
- First Posted Date
- 2014-04-04
- Last Posted Date
- 2016-02-22
- Lead Sponsor
- Janssen Scientific Affairs, LLC
- Target Recruit Count
- 315
- Registration Number
- NCT02103699
A Dose Ranging Escalation Study of Tramadol Hydrochloride in Healthy Volunteers
- First Posted Date
- 2013-09-23
- Last Posted Date
- 2014-12-16
- Lead Sponsor
- Janssen Scientific Affairs, LLC
- Target Recruit Count
- 30
- Registration Number
- NCT01947920
Evaluation of Blood Pressure Reduction, Safety, and Tolerability of Canagliflozin in Patients With Hypertension and Type 2 Diabetes Mellitus on Stable Doses of Anti-hyperglycemic and Anti-hypertensive Agents
Phase 4
Completed
- Conditions
- Diabetes Mellitus, Type 2Hypertension
- Interventions
- Drug: PlaceboDrug: Canagliflozin
- First Posted Date
- 2013-09-11
- Last Posted Date
- 2017-03-03
- Lead Sponsor
- Janssen Scientific Affairs, LLC
- Target Recruit Count
- 171
- Registration Number
- NCT01939496
A Study Exploring Two Strategies of Rivaroxaban (JNJ39039039; BAY-59-7939) and One of Oral Vitamin K Antagonist in Patients With Atrial Fibrillation Who Undergo Percutaneous Coronary Intervention
Phase 3
Completed
- Conditions
- Percutaneous Coronary InterventionAtrial Fibrillation
- Interventions
- First Posted Date
- 2013-04-12
- Last Posted Date
- 2017-09-19
- Lead Sponsor
- Janssen Scientific Affairs, LLC
- Target Recruit Count
- 2124
- Registration Number
- NCT01830543
A Research Study to Bank Samples for Future Evaluation to Identify Biomarkers That Predispose Crohn's Disease and Ulcerative Colitis Patients to Develop Hepatosplenic T-Cell Lymphoma (HSTCL)
- First Posted Date
- 2013-03-05
- Last Posted Date
- 2021-03-04
- Lead Sponsor
- Janssen Scientific Affairs, LLC
- Target Recruit Count
- 1
- Registration Number
- NCT01804166
© Copyright 2025. All Rights Reserved by MedPath